- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Breaking: US Supreme Court to Hear Biosimilars Lawsuits
Which road will the courts take?
Breaking News - as reported by Seeking Alpha:
In what many observers and market players hope will clarify the biosimilar approval route, the U.S. Supreme Court has agreed to hear two related lawsuits over certain Obamacare provisions governing biosimilars.
The dispute centers on Novartis (NVS -0.5%) Sandoz unit's marketing application for its biosimilar to Amgen's (AMGN +0.5%) Neupogen (filgrastim), approved in the U.S. in September 2015. Sandoz is marketing the product under the brand name Zarxio.
Amgen sued Sandoz in an attempt to block Zarxio's approval but failed. The ruling by the U.S. Court of Appeals, which set the approval date, was a bit muddled. Amgen and Sandoz both filed suit against portions of the decision.
The Appeals Court said Sandoz was not required to give Amgen information about its biosimilar application, including a description of the manufacturing process. It added that Amgen could file a patent infringement suit instead (it did so, the trial is set to start in December).
Amgen's position is that the law says Sandoz "shall" give the information and the failure to do so warrants an injunction barring Zarxio sales. Sandoz sued over the requirement that it had to give Amgen 180 days' notice after FDA approval before it could start selling the product.
The specific date of the hearing has not been set.
Source: SeekingAlpha.com
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
